by MM360 Staff | Jun 30, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jun 27, 2025 | Uncategorized
Source: CureToday articles Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. Read More
by MM360 Staff | Jun 27, 2025 | Publications
Cancers (Basel). 2025 Jun 11;17(12):1943. doi: 10.3390/cancers17121943. ABSTRACT Background: Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to standard first-line triplet regimens, including a proteasome inhibitor (PI), an immunomodulatory drug...
by MM360 Staff | Jun 27, 2025 | Myeloma News
Source: Pharmacy Times articles Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study. Read More
by MM360 Staff | Jun 26, 2025 | Myeloma News
Source: Pharmacy Times articles Data from a phase 1b study showed significantly reduced toxicity compared with conventional oral dosing. Read More